Skip to main content

Advertisement

Log in

Attention-Deficit/Hyperactivity Disorder in Older Adults: Prevalence and Possible Connections to Mild Cognitive Impairment

  • Attention-Deficit Disorder (R Bussing, Section Editor)
  • Published:
Current Psychiatry Reports Aims and scope Submit manuscript

Abstract

Attentional deficits are frequently seen in isolation as the presenting sign and symptom of neurodegenerative disease, manifest as mild cognitive impairment (MCI). Persistent ADHD in the geriatric population could well be misconstrued as MCI, leading to the incorrect assumption that such persons are succumbing to a neurodegenerative disease process. Alternatively, the molecular, neuroanatomic, or neurochemical abnormalities seen in ADHD may contribute to the development of de novo late life neurodegenerative disease. The present review examines the issue of causality vs confound regarding the association of ADHD with MCI, suggesting that both are tenable hypotheses.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance, •• Of outstanding importance

  1. Increasing prevalence of parent-reported attention-deficit/hyperactivity disorder among children—United States, 2003 and 2007. MMWR Morb Mortal Wkly Rep. 2010;59:1439–43.

  2. Freitag CM, Rohde LA, Lempp T, et al. Phenotypic and measurement influences on heritability estimates in childhood ADHD. Eur Child Adolesc Psychiatry. 2010;19:311–23.

    Article  PubMed  Google Scholar 

  3. • Wilens TE, Spencer TJ. Understanding attention-deficit/hyperactivity disorder from childhood to adulthood. Postgrad Med. 2010;122:97–109. This general review of ADHD across the lifespan can help orient the reader to current clinical conceptualization and medical practice of this disorder. The general overview of practical clinical information for diagnosis and treatment is comprehensive and yet understandable for the lay practitioner that lacks specific expertise in the area of ADHD.

    Article  PubMed  Google Scholar 

  4. Kleschevnikov AM, Belichenko PV, Salehi A, et al. Discoveries in down syndrome: moving basic science to clinical care. Prog Brain Res. 2012;197:199–221.

    Article  PubMed  CAS  Google Scholar 

  5. Nieuwenhuis-Mark RE. Diagnosing Alzheimer's dementia in Down syndrome: problems and possible solutions. Res Dev Disabil. 2009;30:827–38.

    Article  PubMed  Google Scholar 

  6. Jicha GAaP, R.C. Mild cognitive impairment. In: Growdon JaR, M, editors. The dementias 2. Massachusetts: Elsevier Inc; 2007.

  7. Petersen RC. Mild cognitive impairment: current research and clinical implications. Semin Neurol. 2007;27:22–31.

    Article  PubMed  Google Scholar 

  8. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303–8.

    Article  PubMed  CAS  Google Scholar 

  9. Petersen RC, Stevens JC, Ganguli M, et al. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1133–42.

    Article  PubMed  CAS  Google Scholar 

  10. Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment–beyond controversies, towards a consensus: report of the international working group on mild cognitive impairment. J Int Med. 2004;256:240–6.

    Article  CAS  Google Scholar 

  11. Faraone SV, Sergeant J, Gillberg C, et al. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry. 2003;2:104–13.

    PubMed  Google Scholar 

  12. Weiss G, Hechtman L, Milroy T, et al. Psychiatric status of hyperactives as adults: a controlled prospective 15-year follow-up of 63 hyperactive children. J Am Acad Child Adolesc Psychiatry. 1985;24:211–20.

    Article  CAS  Google Scholar 

  13. Kessler RC, Adler LA, Barkley R, et al. Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the national comorbidity survey replication. Biol Psychiatry. 2005;57:1442–51.

    Article  PubMed  Google Scholar 

  14. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the national comorbidity survey replication. Am J Psychiatry. 2006;163:716–23.

    Article  PubMed  Google Scholar 

  15. •• Ivanchak N, Abner EL, Carr SA, et al. Attention-deficit/hyperactivity disorder in childhood is associated with cognitive test profiles in the geriatric population but not with mild cognitive impairment or Alzheimer's disease. J Aging Res 2011. doi:10.4061/2011/729801. This manuscript represents the first and only published report on the association of childhood ADHD with the development of late-life mild cognitive impairment. The findings demonstrate the persistence of ADHD traits well into geriatric years, as evidenced by specific attentional deficits on neuropsychological tests. Importantly, the authors found no association between ADHD and the diagnosis of MCI or Alzheimer’s disease, suggesting that late life cognitive decline is independent of the early childhood manifestations and late life persistence of ADHD traits.

    CAS  Google Scholar 

  16. Diagnostic and statistical manual of mental disorders. Washington, D.C.: American Psychiatric Association. 1994.

  17. Ward MF, Wender PH, Reimherr FW. The Wender Utah rating scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder. Am J Psychiatry. 1993;150:885–90.

    PubMed  CAS  Google Scholar 

  18. Murphy P, Schachar R. Use of self-ratings in the assessment of symptoms of attention deficit hyperactivity disorder in adults. Am J Psychiatry. 2000;157:1156–9.

    Article  PubMed  CAS  Google Scholar 

  19. Conners CK. Clinical use of rating scales in diagnosis and treatment of attention-deficit/hyperactivity disorder. Pediatr Clin North Am. 1999;46:857–70. vi.

    Article  PubMed  CAS  Google Scholar 

  20. Murphy KR, Adler LA. Assessing attention-deficit/hyperactivity disorder in adults: focus on rating scales. J Clin Psychiatry. 2004;65(Suppl):12–7.

    PubMed  Google Scholar 

  21. Spencer T, Biederman J, Wilens T. Attention-deficit/hyperactivity disorder and comorbidity. Pediatr Clin North Am. 1999;46:915–27. vii.

    Article  PubMed  CAS  Google Scholar 

  22. Kessler RC, Green JG, Adler LA, et al. Structure and diagnosis of adult attention-deficit/hyperactivity disorder: analysis of expanded symptom criteria from the adult ADHD clinical diagnostic scale. Arch Gen Psychiatry. 2010;67:1168–78.

    Article  PubMed  Google Scholar 

  23. Primich C, Iennaco J. Diagnosing adult attention-deficit hyperactivity disorder: the importance of establishing daily life contexts for symptoms and impairments. J Psychiatr Ment Health Nurs. 2012;19:362–73.

    Article  PubMed  CAS  Google Scholar 

  24. Konrad K, Eickhoff SB. Is the ADHD brain wired differently? A review on structural and functional connectivity in attention deficit hyperactivity disorder. Hum Brain Mapp. 2010;31:904–16.

    Article  PubMed  Google Scholar 

  25. Ivanchak N, Abner EL, Carr SA, et al. Attention-deficit/hyperactivity disorder in childhood is associated with cognitive test profiles in the geriatric population but not with mild cognitive impairment or Alzheimer's disease. J Aging Res. 2011;2011:729801.

    PubMed  CAS  Google Scholar 

  26. Bramham J, Murphy DG, Xenitidis K, et al. Adults with attention deficit hyperactivity disorder: an investigation of age-related differences in behavioral symptoms, neuropsychological function and co-morbidity. Psychol Med. 2012. doi:10.1017/S0033291712000219.

  27. Biederman J. Impact of comorbidity in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2004;65(Suppl):3–7.

    PubMed  Google Scholar 

  28. McGough JJ, Smalley SL, McCracken JT, et al. Psychiatric comorbidity in adult attention deficit hyperactivity disorder: findings from multiplex families. Am J Psychiatry. 2005;162:1621–7.

    Article  PubMed  Google Scholar 

  29. Biederman J, Faraone SV, Spencer T, et al. Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry. 1993;150:1792–8.

    PubMed  CAS  Google Scholar 

  30. Alpert JE, Maddocks A, Nierenberg AA, et al. Attention deficit hyperactivity disorder in childhood among adults with major depression. Psychiatry Res. 1996;62:213–9.

    Article  PubMed  CAS  Google Scholar 

  31. Van Ameringen M, Mancini C, Simpson W, et al. Adult attention deficit hyperactivity disorder in an anxiety disorders population. CNS Neurosci Ther. 2011;17:221–6.

    Article  PubMed  Google Scholar 

  32. Biederman J, Ball SW, Monuteaux MC, et al. New insights into the comorbidity between ADHD and major depression in adolescent and young adult females. J Am Acad Child Adolesc Psychiatry. 2008;47:426–34.

    Article  PubMed  Google Scholar 

  33. Murphy K, Barkley RA. Attention deficit hyperactivity disorder adults: comorbidities and adaptive impairments. Compr Psychiatry. 1996;37:393–401.

    Article  PubMed  CAS  Google Scholar 

  34. Hennessey KA, Stein MD, Rosengard C, et al. Childhood attention deficit hyperactivity disorder, substance use, and adult functioning among incarcerated women. J Atten Disord. 2010;14:273–80.

    Article  PubMed  Google Scholar 

  35. Petersen RC, Roberts RO, Knopman DS, et al. Prevalence of mild cognitive impairment is higher in men. The Mayo Clinic Study of Aging. Neurology. 2010;75:889–97.

    Article  PubMed  CAS  Google Scholar 

  36. Rocca WA, Petersen RC, Knopman DS, et al. Trends in the incidence and prevalence of Alzheimer's disease, dementia, and cognitive impairment in the United States. Alzheimers Dement. 2011;7:80–93.

    Article  PubMed  Google Scholar 

  37. Busse A, Bischkopf J, Riedel-Heller SG, et al. Subclassifications for mild cognitive impairment: prevalence and predictive validity. Psychol Med. 2003;33:1029–38.

    Article  PubMed  CAS  Google Scholar 

  38. Portet F, Ousset PJ, Visser PJ, et al. Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI working group of the European consortium on Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2006;77:714–8.

    Article  PubMed  CAS  Google Scholar 

  39. Stephan BC, Matthews FE, McKeith IG, et al. Early cognitive change in the general population: how do different definitions work? J Am Geriatr Soc. 2007;55:1534–40.

    Article  PubMed  Google Scholar 

  40. Jicha GA, Abner E, Schmitt FA, et al. Clinical features of mild cognitive impairment differ in the research and tertiary clinic settings. Dement Geriatr Cogn Disord. 2008;26:187–92.

    Article  PubMed  CAS  Google Scholar 

  41. •• Golimstok A, Rojas JI, Romano M, et al. Previous adult attention-deficit and hyperactivity disorder symptoms and risk of dementia with Lewy bodies: a case-control study. Eur J Neurol. 2011;18:78–84. The data presented suggest an association between childhood ADHD and late life dementia with Lewy Bodies. No such association was found with late life Alzheimer’s disease. The conclusions suggest that possible associations between childhood ADHD and late life degenerative disease may be restricted to specific degenerative disease states.

    Article  PubMed  CAS  Google Scholar 

  42. Jicha GA, Schmitt FA, Abner E, et al. Prodromal clinical manifestations of neuropathologically confirmed Lewy body disease. Neurobiol Aging. 2010;31:1805–13.

    Article  PubMed  CAS  Google Scholar 

  43. Molano J, Boeve B, Ferman T, et al. Mild cognitive impairment associated with limbic and neocortical Lewy body disease: a clinicopathological study. Brain. 2010;133:540–56.

    Article  PubMed  Google Scholar 

  44. Williams LM, Tsang TW, Clarke S, et al. An 'integrative neuroscience' perspective on ADHD: linking cognition, emotion, brain and genetic measures with implications for clinical support. Expert Rev Neurother. 2010;10:1607–21.

    Article  PubMed  Google Scholar 

  45. Hudziak JJ, Derks EM, Althoff RR, et al. The genetic and environmental contributions to attention deficit hyperactivity disorder as measured by the Conners' Rating Scales–Revised. Am J Psychiatry. 2005;162:1614–20.

    Article  PubMed  Google Scholar 

  46. Thapar A, Fowler T, Rice F, et al. Maternal smoking during pregnancy and attention deficit hyperactivity disorder symptoms in offspring. Am J Psychiatry. 2003;160:1985–9.

    Article  PubMed  Google Scholar 

  47. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the quality standards subcommittee of the American Academy of Neurology. Neurology. 2001;56:1143–53.

    Article  PubMed  CAS  Google Scholar 

  48. Hudziak JJ, Heath AC, Madden PF, et al. Latent class and factor analysis of DSM-IV ADHD: a twin study of female adolescents. J Am Acad Child Adolesc Psychiatry. 1998;37:848–57.

    Article  PubMed  CAS  Google Scholar 

  49. Faraone SV, Perlis RH, Doyle AE, et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57:1313–23.

    Article  PubMed  CAS  Google Scholar 

  50. Greven CU, Rijsdijk FV, Plomin R. A twin study of ADHD symptoms in early adolescence: hyperactivity-impulsivity and inattentiveness show substantial genetic overlap but also genetic specificity. J Abnorm Child Psychol. 2011;39:265–75.

    Article  PubMed  Google Scholar 

  51. Boomsma DI, Saviouk V, Hottenga JJ, et al. Genetic epidemiology of attention deficit hyperactivity disorder (ADHD index) in adults. PLoS One. 2010;5:e10621.

    Article  PubMed  Google Scholar 

  52. Dougherty DD, Bonab AA, Spencer TJ, et al. Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet. 1999;354:2132–3.

    Article  PubMed  CAS  Google Scholar 

  53. Genro JP, Kieling C, Rohde LA, et al. Attention-deficit/hyperactivity disorder and the dopaminergic hypotheses. Expert Rev Neurother. 2010;10:587–601.

    Article  PubMed  CAS  Google Scholar 

  54. Lauzon NM, Laviolette SR. Dopamine D4-receptor modulation of cortical neuronal network activity and emotional processing: implications for neuropsychiatric disorders. Behav Brain Res. 2010;208:12–22.

    Article  PubMed  CAS  Google Scholar 

  55. Steinhausen HC. The heterogeneity of causes and courses of attention-deficit/hyperactivity disorder. Acta Psychiatr Scand. 2009;120:392–9.

    Article  PubMed  Google Scholar 

  56. Banaschewski T, Becker K, Scherag S, et al. Molecular genetics of attention-deficit/hyperactivity disorder: an overview. Eur Child Adolesc Psychiatry. 2010;19:237–57.

    Article  PubMed  Google Scholar 

  57. Faraone SV, Mick E. Molecular genetics of attention deficit hyperactivity disorder. Psychiatr Clin North Am. 2010;33:159–80.

    Article  PubMed  Google Scholar 

  58. Lo-Castro A, D'Agati E, Curatolo P. ADHD and genetic syndromes. Brain Dev. 2010.

  59. Naj AC, Jun G, Beecham GW, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet. 2011;43:436–41.

    Article  PubMed  CAS  Google Scholar 

  60. Lee JH, Cheng R, Barral S, et al. Identification of novel loci for Alzheimer disease and replication of CLU, PICALM, and BIN1 in Caribbean Hispanic individuals. Arch Neurol. 2011;68:320–8.

    Article  PubMed  Google Scholar 

  61. Castellanos FXL, Patti P; Sharp W, Jeffries, NO, Greenstein, DK, Clasen LS, et al. Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/hyperactivity disorder. JAMA. 2002;288(14):1740–8.

    Google Scholar 

  62. Strohle A, Stoy M, Wrase J, et al. Reward anticipation and outcomes in adult males with attention-deficit/hyperactivity disorder. NeuroImage. 2008;39:966–72.

    Article  PubMed  Google Scholar 

  63. Vaidya CJB, Silvia A, Dudukovic NM, Zalecki CA, Elliott GR, Grabieli JDE. Altered neural substrates of cognitive control in childhood adhd: evidence from functional magnetic resonance imaging. Am J Psychiatry. 2005;162:1605–13.

    Article  PubMed  Google Scholar 

  64. • Jicha GA, Carr SA. Conceptual evolution in Alzheimer's disease: implications for understanding the clinical phenotype of progressive neurodegenerative disease. J Alzheimers Dis. 2010;19:253–72. This thorough review of AD tracks the biological and clinical phenotype through its course from preclinical AD in cognitively normal individuals to mild cognitive impairment (MCI) to more fulminate AD. It provides an excellent background understanding of the key issues related to late life cognitive decline of the AD-type for the lay practitioner with expertise in ADHD but not in late life degenerative disorders.

    PubMed  Google Scholar 

  65. Biederman J, Spencer T. Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol Psychiatry. 1999;46:1234–42.

    Article  PubMed  CAS  Google Scholar 

  66. Dopheide JA, Pliszka SR. Attention-deficit-hyperactivity disorder: an update. Pharmacotherapy. 2009;29:656–79.

    Article  PubMed  Google Scholar 

  67. Levy F. Dopamine vs noradrenaline: inverted-U effects and ADHD theories. Aust N Z J Psychiatry. 2009;43:101–8.

    Article  PubMed  Google Scholar 

  68. Madras BK, Miller GM, Fischman AJ. The dopamine transporter and attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57:1397–409.

    Article  PubMed  CAS  Google Scholar 

  69. Russell VA. Neurobiology of animal models of attention-deficit hyperactivity disorder. J Neurosci Methods. 2007;161:185–98.

    Article  PubMed  Google Scholar 

  70. Spencer TJ, Biederman J, Madras BK, et al. Further evidence of dopamine transporter dysregulation in ADHD: a controlled PET imaging study using altropane. Biol Psychiatry. 2007;62:1059–61.

    Article  PubMed  CAS  Google Scholar 

  71. Chamberlain SR, Muller U, Blackwell AD, et al. Noradrenergic modulation of working memory and emotional memory in humans. Psychopharmacology. 2006;188:397–407.

    Article  PubMed  CAS  Google Scholar 

  72. Kim CH, Waldman ID, Blakely RD, et al. Functional gene variation in the human norepinephrine transporter: association with Attention Deficit Hyperactivity Disorder. Ann N Y Acad Sci. 2008;1129:256–60.

    Article  PubMed  CAS  Google Scholar 

  73. Oades RD, Sadile AG, Sagvolden T, et al. The control of responsiveness in ADHD by catecholamines: evidence for dopaminergic, noradrenergic, and interactive roles. Dev Sci. 2005;8:122–31.

    Article  PubMed  Google Scholar 

  74. Christman AK, Fermo JD, Markowitz JS. Atomoxetine, a novel treatment for attention-deficit-hyperactivity disorder. Pharmacotherapy. 2004;24:1020–36.

    Article  PubMed  CAS  Google Scholar 

  75. Dell’Agnello G, Zuddas A, Masi G, et al. Use of atomoxetine in patients with attention-deficit hyperactivity disorder and co-morbid conditions. CNS Drugs. 2009;23:739–53.

    Article  PubMed  Google Scholar 

  76. Garnock-Jones KP, Keating GM. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs. 2009;11:203–26.

    Article  PubMed  Google Scholar 

  77. Heal DJ, Pierce DM. Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system. CNS Drugs. 2006;20:713–38.

    Article  PubMed  CAS  Google Scholar 

  78. Kostrzewa RM, Kostrzewa JP, Kostrzewa RA, et al. Pharmacological models of ADHD. J Neural Transm. 2008;115:287–98.

    Article  PubMed  CAS  Google Scholar 

  79. Wilens TE. Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2008;28(Suppl):S46–53.

    Article  PubMed  CAS  Google Scholar 

  80. Braak H, Bohl JR, Muller CM, et al. Stanley Fahn Lecture 2005: the staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov Disord. 2006;21:2042–51.

    Article  PubMed  Google Scholar 

  81. Halliday GM, Del Tredici K, Braak H. Critical appraisal of brain pathology staging related to presymptomatic and symptomatic cases of sporadic Parkinson's disease. J Neural Transm Suppl. 2006:99–103.

  82. • Braak H, Thal DR, Ghebremedhin E, et al. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011;70:960–9. This recent pathological analysis of AD changes demonstrates that the earliest appearance of AD-related changes is in the locus coeruleus, and that such changes can occur in childhood, adolescence, and early adulthood, when ADHD emerges as a clinical entity. This pathological finding is novel and supports a possible link between a hypo-aminergic state caused by AD and the clinical manifestations of ADHD.

    Article  PubMed  CAS  Google Scholar 

  83. Biederman J, Mick E, Faraone S, et al. A double-blind comparison of galantamine hydrogen bromide and placebo in adults with attention-deficit/hyperactivity disorder: a pilot study. J Clin Psychopharmacol. 2006;26:163–6.

    Article  PubMed  CAS  Google Scholar 

  84. Doyle RL, Frazier J, Spencer TJ, et al. Donepezil in the treatment of ADHD-like symptoms in youths with pervasive developmental disorder: a case series. J Atten Disord. 2006;9:543–9.

    Article  PubMed  Google Scholar 

  85. Mohammadi MR, Akhondzadeh S. Pharmacotherapy of attention-deficit/hyperactivity disorder: nonstimulant medication approaches. Expert Rev Neurother. 2007;7:195–201.

    Article  PubMed  CAS  Google Scholar 

  86. Niederhofer H. Combining carbamazepine, neuroleptics and acetylcholinesterase inhibitors with methylphenidate only reduces adverse side effects, but is less effective than a combination with atomoxetine. Med Hypotheses. 2011;76:764–5.

    Article  PubMed  CAS  Google Scholar 

  87. Spencer T, Biederman J. Non-stimulant treatment for attention-deficit/hyperactivity disorder. J Atten Disord. 2002;6(Suppl):S109–19.

    PubMed  Google Scholar 

  88. Wilens TE, Biederman J, Wong J, et al. Adjunctive donepezil in attention deficit hyperactivity disorder youth: case series. J Child Adolesc Psychopharmacol. 2000;10:217–22.

    Article  PubMed  CAS  Google Scholar 

  89. Dolder CR, Davis LN, McKinsey J. Use of psychostimulants in patients with dementia. Ann Pharmacother. 2010;44:1624–32.

    Article  PubMed  CAS  Google Scholar 

  90. Elia J, Vetter VL. Cardiovascular effects of medications for the treatment of attention-deficit hyperactivity disorder: what is known and how should it influence prescribing in children? Paediatr Drugs. 2010;12:165–75.

    Article  PubMed  Google Scholar 

  91. Darvill Jr FT, Woolley S. Double blind evaluation of methylphenidate (ritalin) hydrochloride; its use in the management of institutionalized geriatric patients. J Am Med Assoc. 1959;169:1739–41.

    Article  PubMed  Google Scholar 

  92. Galynker I, Ieronimo C, Miner C, et al. Methylphenidate treatment of negative symptoms in patients with dementia. J Neuropsychiatry Clin Neurosci. 1997;9:231–9.

    PubMed  CAS  Google Scholar 

  93. Goforth HW, Konopka L, Primeau M, et al. Quantitative electroencephalography in frontotemporal dementia with methylphenidate response: a case study. Clin EEG Neurosci. 2004;35:108–11.

    PubMed  Google Scholar 

  94. Herrmann N, Rothenburg LS, Black SE, et al. Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge. J Clin Psychopharmacol. 2008;28:296–301.

    Article  PubMed  CAS  Google Scholar 

  95. Kittur S, Hauser P. Improvement of sleep and behavior by methylphenidate in Alzheimer's disease. Am J Psychiatry. 1999;156:1116–7.

    PubMed  CAS  Google Scholar 

  96. Padala PR, Burke WJ, Shostrom VK, et al. Methylphenidate for apathy and functional status in dementia of the Alzheimer type. Am J Geriatr Psychiatry. 2010;18:371–4.

    Article  PubMed  Google Scholar 

  97. Rahman S, Robbins TW, Hodges JR, et al. Methylphenidate ('Ritalin') can ameliorate abnormal risk-taking behavior in the frontal variant of frontotemporal dementia. Neuropsychopharmacology. 2006;31:651–8.

    Article  PubMed  CAS  Google Scholar 

  98. Watanabe MD, Martin EM, DeLeon OA, et al. Successful methylphenidate treatment of apathy after subcortical infarcts. J Neuropsychiatry Clin Neurosci. 1995;7:502–4.

    PubMed  CAS  Google Scholar 

  99. Prommer E. Methylphenidate: established and expanding roles in symptom management. Am J Hosp Palliat Care. 2011.

  100. Cubo E. Fernandez Jaen A, Moreno C, et al. Donepezil use in children and adolescents with tics and attention-deficit/hyperactivity disorder: an 18-week, single-center, dose-escalating, prospective, open-label study. Clin Ther. 2008;30:182–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported by funding from National Institutes of Health/National Institute on Aging 1 P30 AG028383, National Institutes of Health LRP 1L30 AG032934, and the Sanders-Brown Foundation.

Disclosure

N. Ivanchak: none; K. Fletcher: none; G. A. Jicha: consultant to Eli Lilly and Pfizer, and grants from National Institute on Aging and National Institutes of Health.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Gregory A. Jicha.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ivanchak, N., Fletcher, K. & Jicha, G.A. Attention-Deficit/Hyperactivity Disorder in Older Adults: Prevalence and Possible Connections to Mild Cognitive Impairment. Curr Psychiatry Rep 14, 552–560 (2012). https://doi.org/10.1007/s11920-012-0305-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11920-012-0305-8

Keywords

Navigation